Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company, announced CEO Norbert Riedel's participation in the 'Brains of the Operation - Novel Approaches in Neuro' panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10 at 12:00 p.m. ET.
A live webcast of the discussion will be accessible on Aptinyx's 'Events and Presentations' page for 30 days post-event. The company is focused on developing therapies for nervous system disorders, utilizing proprietary synthetic small molecules to modulate NMDA receptors and enhance synaptic plasticity.
Aptinyx Inc. (Nasdaq: APTX) has announced a conference call scheduled for August 10, 2021, at 5:00 p.m. ET to discuss its second-quarter 2021 financial results and recent business highlights.
The call will be accessible via phone or a live audio webcast on the company's website. Aptinyx specializes in developing therapies for nervous system disorders, with three products in clinical development targeting chronic pain, PTSD, and cognitive impairment.
Aptinyx (Nasdaq: APTX), a biopharmaceutical company, announced that its CEO, Norbert Riedel, Ph.D., will participate in the Updates in Neuropsych panel at the William Blair Biotech Focus Conference on July 15 at 12:00 p.m. ET.
A live webcast of the event will be available on the company's website and archived for 30 days. Aptinyx is focused on developing therapies for nervous system disorders, including chronic pain and PTSD, through a unique mechanism that modulates NMDA receptors, enhancing synaptic plasticity. For more information, visit www.aptinyx.com.
Aptinyx Inc. (Nasdaq: APTX) announced its participation in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13 at 3:40 p.m. ET. A live webcast will be available to Cowen clients. Aptinyx focuses on developing therapies for nervous system disorders, emphasizing a unique mechanism to modulate NMDA receptors. The company has three product candidates targeting chronic pain, PTSD, and cognitive impairment, along with a robust pipeline of small-molecule NMDA receptor modulators aimed at various neurological conditions.
Aptinyx Inc. (Nasdaq: APTX) has announced its participation in two investor conferences. On June 22, CEO Norbert Riedel will join the panel on "Hot Topics in Neurological Disorder Therapeutics and Technologies" at the Oppenheimer Biotech by the Lake 2021 Investor Summit. Following that, on June 29, the management will engage in a fireside chat, "Validating the Mechanism of NMDA Modulation," during the SVB Leerink CNS Forum. Aptinyx is focused on developing therapies for nervous system disorders, with significant clinical candidates targeting chronic pain, PTSD, and cognitive impairment.
Aptinyx Inc. (Nasdaq: APTX) has announced the final design of its Phase 2b program for NYX-783 targeting PTSD, following feedback from the FDA. The studies, set to begin in late 2021 and early 2022, will examine 50 mg and 150 mg doses in approximately 300 patients each. Additionally, an error found in a prior exploratory Phase 2 study's statistical analysis will alter p-values but not study conclusions. NYX-783 showed a significant improvement of 15.7 points (43%) in CAPS-5 scores for the 50 mg dose. Revised analyses confirm the efficacy and safety of NYX-783, maintaining its development trajectory.
Aptinyx Inc. reported its Q1 2021 financial results, showing a net loss of $14.2 million, down from $14.7 million in Q1 2020. The company highlighted pivotal FDA meetings regarding NYX-783 for PTSD, with a Phase 2b study expected to start in 2H 2021. The recommencement of a Phase 2 study for NYX-458 in cognitive impairment associated with Parkinson’s was also noted. Cash and equivalents rose to $146.8 million, projected to fund operations into 2023. Collaboration revenue was $1.0 million, up from $0.8 million year-over-year.
Aptinyx Inc. (Nasdaq: APTX) has elected Dr. Joan W. Miller to its Board of Directors. Dr. Miller is a prominent figure in ophthalmology, serving as the Chair of the Department of Ophthalmology at Harvard Medical School and Chief of Ophthalmology at several leading hospitals. Her extensive background includes developing FDA-approved therapies for age-related macular degeneration and authoring numerous peer-reviewed articles. Aptinyx's CEO, Norbert Riedel, expressed confidence that Dr. Miller's expertise will aid in advancing their therapeutic candidates aimed at central nervous system disorders.
Aptinyx Inc. (Nasdaq: APTX) will host a conference call on May 13, 2021, at 5:00 p.m. ET to discuss its first-quarter 2021 financial results and recent business highlights. The call is accessible by dialing (833) 772-0394 domestically or (236) 738-2205 internationally, using conference ID 3628539. A live audio webcast will also be available on the company’s website, with a replay archived for 30 days. Aptinyx focuses on developing therapies for brain and nervous system disorders using a unique mechanism to enhance synaptic plasticity.
Aptinyx Inc. (NASDAQ: APTX) presented new data from its exploratory Phase 2 study of NYX-783 for post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry Annual Meeting. The study involved 153 patients and demonstrated statistically significant improvements in CAPS-5 Total scores, particularly in the 50 mg treatment group compared to placebo. Key highlights include significantly greater clinically reliable changes and favorable safety profiles. Aptinyx plans to utilize these findings in upcoming larger studies for NYX-783.
